Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett’s Esophagus
Background The rate and risk factors of recurrent or metachronous adenocarcinoma following endoscopic ablation therapy in patients with Barrett’s esophagus (BE) have not been specifically reported. Aim The aim of this study was to determine the incidence and predictors of adenocarcinoma after ablati...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2014-07, Vol.59 (7), p.1560-1566 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1566 |
|---|---|
| container_issue | 7 |
| container_start_page | 1560 |
| container_title | Digestive diseases and sciences |
| container_volume | 59 |
| creator | Yasuda, Kazuhiro Choi, Sung Eun Nishioka, Norman S. Rattner, David W. Puricelli, William P. Tramontano, Angela C. Kitano, Seigo Hur, Chin |
| description | Background
The rate and risk factors of recurrent or metachronous adenocarcinoma following endoscopic ablation therapy in patients with Barrett’s esophagus (BE) have not been specifically reported.
Aim
The aim of this study was to determine the incidence and predictors of adenocarcinoma after ablation therapy for BE high-grade dysplasia (HGD) or intramucosal carcinoma (IMC).
Methods
This is a single center, retrospective review of prospectively collected data on consecutive cases of endoscopic ablation for BE. A total of 223 patients with BE (HGD or IMC) were treated by ablation between 1996 and 2011. Primary outcome measures were recurrence and new development of adenocarcinoma after ablation. Recurrence was defined as the presence of adenocarcinoma following the absence of adenocarcinoma in biopsy samples from two consecutive surveillance endoscopies. Logistic regression analysis was performed to assess predictors of adenocarcinoma after ablation.
Results
One hundred and eighty-three patients were included in the final analysis, and 40 patients were excluded: 22 for palliative ablation, eight lost to follow-up, five for residual carcinoma and five for postoperative state. Median follow-up was 39 months. Recurrence or new development of adenocarcinoma was found in 20 patients (11 %) and the median time to recurrence/development of adenocarcinoma was 11.5 months. Independent predictors of recurrent or metachronous adenocarcinoma were hiatal hernia size ≥ 4 cm (odds ratio 3.649,
P
= 0.0233) and histology (HGD/adenocarcinoma) after first ablation (odds ratio 4.141,
P
= 0.0065).
Conclusions
Adenocarcinoma after endoscopic therapy for HGD or IMC in BE is associated with large hiatal hernia and histology status after initial ablation therapy. |
| doi_str_mv | 10.1007/s10620-013-3002-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4071117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712942438</galeid><sourcerecordid>A712942438</sourcerecordid><originalsourceid>FETCH-LOGICAL-c640t-fc245b6e020de8301daa3e54a5e75c7191c0f114a3cd18300cb2bbcd48e363b03</originalsourceid><addsrcrecordid>eNqFks1u1DAUhS0EokPhAdigSGzYpNzrn_xskIZqCpUqwQLWlmM7qavEHuykiF1fo6_Hk-DRlGqKQMgLWznfOY6vDiEvEU4QoH6bECoKJSArGQAtxSOyQlGzkoqqeUxWgFU-I1ZH5FlKVwDQ1lg9JUeUs1awhq6IOvfaGeu1LZQ3xedojdNziKkIfbHOQtAqaufDpIqzMI7hu_NDsfEmJB22ThfrblSzC37Hv1cx2nn-eXObik0K20s1LOk5edKrMdkXd_sx-Xq2-XL6sbz49OH8dH1R6orDXPaactFVFigY2zBAoxSzgitha6FrbFFDj8gV0wazDrqjXacNbyyrWAfsmLzb526XbrJGWz9HNcptdJOKP2RQTj5UvLuUQ7iWHGpErHPAm7uAGL4tNs1ycknbcVTehiVJbDmlWNGm_T8qOCDFlrGMvv4DvQpL9HkSmWIta1oQB9SgRiud70P-Rb0Llesaab6ZsyZTJ3-h8jJ2cjp427v8_YEB9wYdQ0rR9vfjQJC7Csl9hWSukNxVSIrseXU4x3vH785kgO6BlCU_2Hjwon-m_gILk9D0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1539389053</pqid></control><display><type>article</type><title>Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett’s Esophagus</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Yasuda, Kazuhiro ; Choi, Sung Eun ; Nishioka, Norman S. ; Rattner, David W. ; Puricelli, William P. ; Tramontano, Angela C. ; Kitano, Seigo ; Hur, Chin</creator><creatorcontrib>Yasuda, Kazuhiro ; Choi, Sung Eun ; Nishioka, Norman S. ; Rattner, David W. ; Puricelli, William P. ; Tramontano, Angela C. ; Kitano, Seigo ; Hur, Chin</creatorcontrib><description>Background
The rate and risk factors of recurrent or metachronous adenocarcinoma following endoscopic ablation therapy in patients with Barrett’s esophagus (BE) have not been specifically reported.
Aim
The aim of this study was to determine the incidence and predictors of adenocarcinoma after ablation therapy for BE high-grade dysplasia (HGD) or intramucosal carcinoma (IMC).
Methods
This is a single center, retrospective review of prospectively collected data on consecutive cases of endoscopic ablation for BE. A total of 223 patients with BE (HGD or IMC) were treated by ablation between 1996 and 2011. Primary outcome measures were recurrence and new development of adenocarcinoma after ablation. Recurrence was defined as the presence of adenocarcinoma following the absence of adenocarcinoma in biopsy samples from two consecutive surveillance endoscopies. Logistic regression analysis was performed to assess predictors of adenocarcinoma after ablation.
Results
One hundred and eighty-three patients were included in the final analysis, and 40 patients were excluded: 22 for palliative ablation, eight lost to follow-up, five for residual carcinoma and five for postoperative state. Median follow-up was 39 months. Recurrence or new development of adenocarcinoma was found in 20 patients (11 %) and the median time to recurrence/development of adenocarcinoma was 11.5 months. Independent predictors of recurrent or metachronous adenocarcinoma were hiatal hernia size ≥ 4 cm (odds ratio 3.649,
P
= 0.0233) and histology (HGD/adenocarcinoma) after first ablation (odds ratio 4.141,
P
= 0.0065).
Conclusions
Adenocarcinoma after endoscopic therapy for HGD or IMC in BE is associated with large hiatal hernia and histology status after initial ablation therapy.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-013-3002-5</identifier><identifier>PMID: 24395382</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Ablation (Surgery) ; Adenocarcinoma ; Adenocarcinoma - epidemiology ; Adenocarcinoma - etiology ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Barrett Esophagus - pathology ; Barrett Esophagus - surgery ; Biochemistry ; Care and treatment ; Catheter Ablation ; Development and progression ; Dysplasia ; Endoscopy ; Esophageal Neoplasms - epidemiology ; Esophageal Neoplasms - etiology ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - surgery ; Esophagoscopy ; Female ; Follow-Up Studies ; Gastroenterology ; Hepatology ; Hernia ; Hernia, Hiatal - complications ; Humans ; Incidence ; Kaplan-Meier Estimate ; Logistic Models ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local ; Oncology ; Original Article ; Pneumoviridae ; Precancerous Conditions - pathology ; Precancerous Conditions - surgery ; Retrospective Studies ; Risk Factors ; Transplant Surgery ; Treatment Outcome</subject><ispartof>Digestive diseases and sciences, 2014-07, Vol.59 (7), p.1560-1566</ispartof><rights>Springer Science+Business Media New York 2014</rights><rights>COPYRIGHT 2014 Springer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c640t-fc245b6e020de8301daa3e54a5e75c7191c0f114a3cd18300cb2bbcd48e363b03</citedby><cites>FETCH-LOGICAL-c640t-fc245b6e020de8301daa3e54a5e75c7191c0f114a3cd18300cb2bbcd48e363b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10620-013-3002-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10620-013-3002-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24395382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yasuda, Kazuhiro</creatorcontrib><creatorcontrib>Choi, Sung Eun</creatorcontrib><creatorcontrib>Nishioka, Norman S.</creatorcontrib><creatorcontrib>Rattner, David W.</creatorcontrib><creatorcontrib>Puricelli, William P.</creatorcontrib><creatorcontrib>Tramontano, Angela C.</creatorcontrib><creatorcontrib>Kitano, Seigo</creatorcontrib><creatorcontrib>Hur, Chin</creatorcontrib><title>Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett’s Esophagus</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Background
The rate and risk factors of recurrent or metachronous adenocarcinoma following endoscopic ablation therapy in patients with Barrett’s esophagus (BE) have not been specifically reported.
Aim
The aim of this study was to determine the incidence and predictors of adenocarcinoma after ablation therapy for BE high-grade dysplasia (HGD) or intramucosal carcinoma (IMC).
Methods
This is a single center, retrospective review of prospectively collected data on consecutive cases of endoscopic ablation for BE. A total of 223 patients with BE (HGD or IMC) were treated by ablation between 1996 and 2011. Primary outcome measures were recurrence and new development of adenocarcinoma after ablation. Recurrence was defined as the presence of adenocarcinoma following the absence of adenocarcinoma in biopsy samples from two consecutive surveillance endoscopies. Logistic regression analysis was performed to assess predictors of adenocarcinoma after ablation.
Results
One hundred and eighty-three patients were included in the final analysis, and 40 patients were excluded: 22 for palliative ablation, eight lost to follow-up, five for residual carcinoma and five for postoperative state. Median follow-up was 39 months. Recurrence or new development of adenocarcinoma was found in 20 patients (11 %) and the median time to recurrence/development of adenocarcinoma was 11.5 months. Independent predictors of recurrent or metachronous adenocarcinoma were hiatal hernia size ≥ 4 cm (odds ratio 3.649,
P
= 0.0233) and histology (HGD/adenocarcinoma) after first ablation (odds ratio 4.141,
P
= 0.0065).
Conclusions
Adenocarcinoma after endoscopic therapy for HGD or IMC in BE is associated with large hiatal hernia and histology status after initial ablation therapy.</description><subject>Ablation (Surgery)</subject><subject>Adenocarcinoma</subject><subject>Adenocarcinoma - epidemiology</subject><subject>Adenocarcinoma - etiology</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Barrett Esophagus - pathology</subject><subject>Barrett Esophagus - surgery</subject><subject>Biochemistry</subject><subject>Care and treatment</subject><subject>Catheter Ablation</subject><subject>Development and progression</subject><subject>Dysplasia</subject><subject>Endoscopy</subject><subject>Esophageal Neoplasms - epidemiology</subject><subject>Esophageal Neoplasms - etiology</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - surgery</subject><subject>Esophagoscopy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Hernia</subject><subject>Hernia, Hiatal - complications</subject><subject>Humans</subject><subject>Incidence</subject><subject>Kaplan-Meier Estimate</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pneumoviridae</subject><subject>Precancerous Conditions - pathology</subject><subject>Precancerous Conditions - surgery</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Transplant Surgery</subject><subject>Treatment Outcome</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFks1u1DAUhS0EokPhAdigSGzYpNzrn_xskIZqCpUqwQLWlmM7qavEHuykiF1fo6_Hk-DRlGqKQMgLWznfOY6vDiEvEU4QoH6bECoKJSArGQAtxSOyQlGzkoqqeUxWgFU-I1ZH5FlKVwDQ1lg9JUeUs1awhq6IOvfaGeu1LZQ3xedojdNziKkIfbHOQtAqaufDpIqzMI7hu_NDsfEmJB22ThfrblSzC37Hv1cx2nn-eXObik0K20s1LOk5edKrMdkXd_sx-Xq2-XL6sbz49OH8dH1R6orDXPaactFVFigY2zBAoxSzgitha6FrbFFDj8gV0wazDrqjXacNbyyrWAfsmLzb526XbrJGWz9HNcptdJOKP2RQTj5UvLuUQ7iWHGpErHPAm7uAGL4tNs1ycknbcVTehiVJbDmlWNGm_T8qOCDFlrGMvv4DvQpL9HkSmWIta1oQB9SgRiud70P-Rb0Llesaab6ZsyZTJ3-h8jJ2cjp427v8_YEB9wYdQ0rR9vfjQJC7Csl9hWSukNxVSIrseXU4x3vH785kgO6BlCU_2Hjwon-m_gILk9D0</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Yasuda, Kazuhiro</creator><creator>Choi, Sung Eun</creator><creator>Nishioka, Norman S.</creator><creator>Rattner, David W.</creator><creator>Puricelli, William P.</creator><creator>Tramontano, Angela C.</creator><creator>Kitano, Seigo</creator><creator>Hur, Chin</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20140701</creationdate><title>Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett’s Esophagus</title><author>Yasuda, Kazuhiro ; Choi, Sung Eun ; Nishioka, Norman S. ; Rattner, David W. ; Puricelli, William P. ; Tramontano, Angela C. ; Kitano, Seigo ; Hur, Chin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c640t-fc245b6e020de8301daa3e54a5e75c7191c0f114a3cd18300cb2bbcd48e363b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Ablation (Surgery)</topic><topic>Adenocarcinoma</topic><topic>Adenocarcinoma - epidemiology</topic><topic>Adenocarcinoma - etiology</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Barrett Esophagus - pathology</topic><topic>Barrett Esophagus - surgery</topic><topic>Biochemistry</topic><topic>Care and treatment</topic><topic>Catheter Ablation</topic><topic>Development and progression</topic><topic>Dysplasia</topic><topic>Endoscopy</topic><topic>Esophageal Neoplasms - epidemiology</topic><topic>Esophageal Neoplasms - etiology</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - surgery</topic><topic>Esophagoscopy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Hernia</topic><topic>Hernia, Hiatal - complications</topic><topic>Humans</topic><topic>Incidence</topic><topic>Kaplan-Meier Estimate</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pneumoviridae</topic><topic>Precancerous Conditions - pathology</topic><topic>Precancerous Conditions - surgery</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Transplant Surgery</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yasuda, Kazuhiro</creatorcontrib><creatorcontrib>Choi, Sung Eun</creatorcontrib><creatorcontrib>Nishioka, Norman S.</creatorcontrib><creatorcontrib>Rattner, David W.</creatorcontrib><creatorcontrib>Puricelli, William P.</creatorcontrib><creatorcontrib>Tramontano, Angela C.</creatorcontrib><creatorcontrib>Kitano, Seigo</creatorcontrib><creatorcontrib>Hur, Chin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yasuda, Kazuhiro</au><au>Choi, Sung Eun</au><au>Nishioka, Norman S.</au><au>Rattner, David W.</au><au>Puricelli, William P.</au><au>Tramontano, Angela C.</au><au>Kitano, Seigo</au><au>Hur, Chin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett’s Esophagus</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>59</volume><issue>7</issue><spage>1560</spage><epage>1566</epage><pages>1560-1566</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>Background
The rate and risk factors of recurrent or metachronous adenocarcinoma following endoscopic ablation therapy in patients with Barrett’s esophagus (BE) have not been specifically reported.
Aim
The aim of this study was to determine the incidence and predictors of adenocarcinoma after ablation therapy for BE high-grade dysplasia (HGD) or intramucosal carcinoma (IMC).
Methods
This is a single center, retrospective review of prospectively collected data on consecutive cases of endoscopic ablation for BE. A total of 223 patients with BE (HGD or IMC) were treated by ablation between 1996 and 2011. Primary outcome measures were recurrence and new development of adenocarcinoma after ablation. Recurrence was defined as the presence of adenocarcinoma following the absence of adenocarcinoma in biopsy samples from two consecutive surveillance endoscopies. Logistic regression analysis was performed to assess predictors of adenocarcinoma after ablation.
Results
One hundred and eighty-three patients were included in the final analysis, and 40 patients were excluded: 22 for palliative ablation, eight lost to follow-up, five for residual carcinoma and five for postoperative state. Median follow-up was 39 months. Recurrence or new development of adenocarcinoma was found in 20 patients (11 %) and the median time to recurrence/development of adenocarcinoma was 11.5 months. Independent predictors of recurrent or metachronous adenocarcinoma were hiatal hernia size ≥ 4 cm (odds ratio 3.649,
P
= 0.0233) and histology (HGD/adenocarcinoma) after first ablation (odds ratio 4.141,
P
= 0.0065).
Conclusions
Adenocarcinoma after endoscopic therapy for HGD or IMC in BE is associated with large hiatal hernia and histology status after initial ablation therapy.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24395382</pmid><doi>10.1007/s10620-013-3002-5</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2014-07, Vol.59 (7), p.1560-1566 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4071117 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Ablation (Surgery) Adenocarcinoma Adenocarcinoma - epidemiology Adenocarcinoma - etiology Adenocarcinoma - pathology Adenocarcinoma - surgery Adult Aged Aged, 80 and over Barrett Esophagus - pathology Barrett Esophagus - surgery Biochemistry Care and treatment Catheter Ablation Development and progression Dysplasia Endoscopy Esophageal Neoplasms - epidemiology Esophageal Neoplasms - etiology Esophageal Neoplasms - pathology Esophageal Neoplasms - surgery Esophagoscopy Female Follow-Up Studies Gastroenterology Hepatology Hernia Hernia, Hiatal - complications Humans Incidence Kaplan-Meier Estimate Logistic Models Male Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local Oncology Original Article Pneumoviridae Precancerous Conditions - pathology Precancerous Conditions - surgery Retrospective Studies Risk Factors Transplant Surgery Treatment Outcome |
| title | Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett’s Esophagus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A35%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20and%20Predictors%20of%20Adenocarcinoma%20Following%20Endoscopic%20Ablation%20of%20Barrett%E2%80%99s%20Esophagus&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Yasuda,%20Kazuhiro&rft.date=2014-07-01&rft.volume=59&rft.issue=7&rft.spage=1560&rft.epage=1566&rft.pages=1560-1566&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1007/s10620-013-3002-5&rft_dat=%3Cgale_pubme%3EA712942438%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1539389053&rft_id=info:pmid/24395382&rft_galeid=A712942438&rfr_iscdi=true |